Status
Ongoing
With financial support from Stichting tegen Kanker (Foundation against Cancer), the Belgian Cancer Registry (BCR) is evaluating the quality of care and outcomes for patients diagnosed with a gastrointestinal stromal tumour (GIST), a soft tissue sarcoma or a bone sarcoma in Belgium. This is the first time the care of patients with a sarcoma has been described at the national level. Sarcomas are a heterogeneous group of rare tumours that require a specific approach from a specialised team of doctors due to the difficulty of diagnosis.
In collaboration with a group of clinical experts, a list of relevant indicators was drawn up to describe the diagnosis, treatment and survival of patients with sarcoma. These indicators are calculated for GIST, soft tissue and bone sarcomas, both at the national level and for individual Belgian hospitals. In addition, the possible association between patient volume and indicator result is also studied.
To arrive at these results, BCR uses cancer registration data and administrative data sources, including reimbursement data from insurance institutions obtained from the Agence InterMutualiste (AIM) (the agency responsible for collating data from Belgium’s seven health insurance funds) and vital status data from the Crossroads Bank for Social Security (CBSS).
Eventually, the results of this survey will be compiled into an overall report. All Belgian hospitals providing care to patients with sarcoma will also receive an individual feedback report. The different centres will be able to use this feedback report to evaluate their own results and compare them with anonymised results from other hospitals in Belgium (benchmarking).
In collaboration with a group of clinical experts, a list of relevant indicators was drawn up to describe the diagnosis, treatment and survival of patients with sarcoma. These indicators are calculated for GIST, soft tissue and bone sarcomas, both at the national level and for individual Belgian hospitals. In addition, the possible association between patient volume and indicator result is also studied.
To arrive at these results, BCR uses cancer registration data and administrative data sources, including reimbursement data from insurance institutions obtained from the Agence InterMutualiste (AIM) (the agency responsible for collating data from Belgium’s seven health insurance funds) and vital status data from the Crossroads Bank for Social Security (CBSS).
Eventually, the results of this survey will be compiled into an overall report. All Belgian hospitals providing care to patients with sarcoma will also receive an individual feedback report. The different centres will be able to use this feedback report to evaluate their own results and compare them with anonymised results from other hospitals in Belgium (benchmarking).
Quality of care